Skip to content
Triangle logo TriangleGet started
← Study library

NCT02047253 · REGISTRY CONDITION SEARCH

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2018-12-19

This study will test how effective the drug, Carfilzomib, reduces progression of prostate cancer in patients who have previously received chemotherapy and androgen inhibitors. Carfilzomib is approved for multiple myeloma but is not approved for prostate cancer. Therefore, it is considered investigational. Other approved methods of treatment for metastatic prostate cancer have demonstrated only modest benefits. Novel and tolerable agents are necessary to make further gains and extend overall survival.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Progression-free Survival (PFS)

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Number of Participants With Prostate-Specific Antigen (PSA) Changes

→

outcome · POSTED

Number of Participants With Circulating Tumor Cell (CTC) Decline Over Three Time Points (Before Study Initiation, Day 1 of Cycles 2 and 4

→

outcome · POSTED

Assessment of Toxicities

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Histologically proven adenocarcinoma of the prostate * Metastatic disease * Progressive disease (PSA, radiologic, symptomatic) following abiraterone acetate and/or Enzalutamide (prior sipuleucel-T and chemotherapy are allowed); PSA progression is defined as baseline increase followed by any PSA increase ≥1 week apart. * Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. * Patients, even if surgically sterilized (i.e., status post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse if female partner of childbearing age. * An elevated PSA level of \>2ng/mL for patients progressing by PSA criteria is required (last confirmatory sample must be \>2ng/mL) * Currently on androgen ablation hormone therapy (a luteinizing hormone- releasing hormone (LHRH) agonist/antagonist or orchiectomy) with testosterone level \<50ng/dL) * Has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 - 2 * Left ventricular ejection fraction (LVEF) ≥40% on 2-D transthoracic echocardiogram (ECHO); Multi-gated Acquisition Scan (MUGA) is acceptable if ECHO is not available. * ≥19 years of age * Resolution of all acute toxic effects of prior chemotherapy or surgical procedures to NCI CTCAE Version 4.03 Grade \<1, in the opinion of the treating physician. * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Patient has a platelet count of \<100,000/mm3, or absolute neutrophil count of \<1500/mm3 or Hemoglobin \<8.0gm/dL * Patient has a calculated or measured creatinine clearance of \<30 milliliters (mL)/minute * Patient has total bilirubin \>2 x upper limit of normal (ULN), or aspartate aminotransferase (AST), alanine aminotransferase (ALT) \>3.5 x ULN * Patient has ≥ Grade 2 peripheral neuropathy within 14 days before enrollment * Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Before study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant. * Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial. * Serious medical or psychiatric illness likely to interfere with participation in this clinical study. * Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of: a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the breast; c) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas. * Known HIV, hepatitis B and hepatitis C infection * Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to randomization * Prior treatment with bortezomib * Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize Carfilzomib) * Has received prior radiation to \>50% of the bone marrow * Has had significant bleeding/thrombosis in previous 4 weeks * Has received treatment with radiation therapy, surgery, chemotherapy, or an investigational agent within 4 weeks prior to registration, (6 weeks for radiation therapy, radionuclides, nitrosoureas, or Mitomycin C) or who have not recovered from adverse events due to agents administered more than 4 weeks earlier * Has evidence of uncontrolled Central Nervous System (CNS) involvement (previous radiation and off steroids is acceptable) * Patients may not be receiving any other investigational agents * Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection * Is unable to comply with study requirements * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
healthy Volunteers
false
minimum Age
19 Years
sex
MALE
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Carfilzomib is administered twice-weekly on consecutive days (days 1, 2, 8, 9, 15, 16) as a 30-minute intravenous infusion for 3 weeks every 4 weeks (1 cycle) with dexamethasone given as pre-medication. The dose of carfilzomib is 20 mg/m2 on days 1 and 2 of cycle 1 and is then escalated in succeeding weeks and cycles to 56 mg/m2 if no dose limiting toxicities occur. Acyclovir is given orally at 400 mg twice daily during therapy but may be discontinued at some point. Therapy will continue until side effects become unacceptable, the disease progresses, or the doctor withdraws the patient.
    intervention Names
    1. Drug: Carfilzomib
    2. Drug: Dexamethasone
    3. Drug: Acyclovir
    label
    Carfilzomib
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Carfilzomib
    description
    Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.
    name
    Carfilzomib
    other Names
    1. Kyprolis
    type
    DRUG
  2. arm Group Labels
    1. Carfilzomib
    description
    Administered prior to administration of Study drug
    name
    Dexamethasone
    type
    DRUG
  3. arm Group Labels
    1. Carfilzomib
    description
    Administered orally twice daily
    name
    Acyclovir
    other Names
    1. Zovirax
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
28
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    The study will measure patient survival at 6 months but will continue to monitor overall survival as a secondary objective. The Kaplan-Meier method will be used.
    measure
    Progression-free Survival (PFS)
    time Frame
    Baseline through 6 months for evaluating all patients
  2. description
    Outcome measure was completed by using a count of participants.
    measure
    Overall Survival
    time Frame
    From baseline through 36 months.
secondary Outcomes
  1. description
    PSA levels were collected at each visit on the day of treatment. Linear regression with PSA as the dependent variable and time as the dependent variable was performed.
    measure
    Number of Participants With Prostate-Specific Antigen (PSA) Changes
    time Frame
    Baseline through 36 months
  2. description
    The CTC marker will be used to evaluate efficacy of response to treatment. CTC changes will include changes from unfavorable (less than or equal to 5/7.5 ml) to favorable and declines by \>30%. Three collections: before study initiation, Day 1 of Cycles 2 and 4
    measure
    Number of Participants With Circulating Tumor Cell (CTC) Decline Over Three Time Points (Before Study Initiation, Day 1 of Cycles 2 and 4
    time Frame
    Baseline through 36 months
  3. description
    Hematologic and non-hematologic toxicities will be graded. The new international criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) will serve as the guideline. On Day 1 of each cycle (4 weeks) for the duration of treatment and then 30 days following the last treatment
    measure
    Assessment of Toxicities
    time Frame
    Baseline through 36 months
Full study description
brief Summary
This study will test how effective the drug, Carfilzomib, reduces progression of prostate cancer in patients who have previously received chemotherapy and androgen inhibitors. Carfilzomib is approved for multiple myeloma but is not approved for prostate cancer. Therefore, it is considered investigational. Other approved methods of treatment for metastatic prostate cancer have demonstrated only modest benefits. Novel and tolerable agents are necessary to make further gains and extend overall survival.
detailed Description
First-line chemotherapy for metastatic castration-resistant prostate cancer (CRPC) combined with androgen inhibitors modestly extends overall survival. Carfilzomib is anticipated to enhance progression-free survival (PFS) as well as reduce pain and toxicities. Proteasome inhibitors are promising agents used in the therapy of prostate cancer. Carfilzomib is a more potent and irreversible proteasome inhibitor than the frequently used proteasome inhibitor, Bortezomib. In Phase I trials Carfilzomib demonstrated substantial antitumor activity while exhibiting tolerable side effects. Carfilzomib has been approved by the FDA for patients with multiple myeloma. The drug, however, is not approved for the use with CRPC patients. This trial will evaluate the tolerance and effectiveness of Carfilzomib in men with metastatic progressive CRPC following chemotherapy and androgen inhibitors.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-8f109d24470bc891fb33
      requested nct id
      NCT02047253
      primary nct id
      NCT02047253
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
      payload sha256
      2a26ef18403e3aad9887ab72f4e7d4d997fb5ca071141b43f0b509538a2a2660
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-8f109d24470bc891fb33
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02047253
      occurrences
      1. context exact
        NCT02047253
        end
        11
        exact text
        NCT02047253
        start
        0
      offset unit
      unicode_code_points
      query cond
      Salivary Gland Cancer
      query disease state id
      ds-salivary-gland-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-salivary-gland-cancer-000.json
      source file sha256
      38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
      source json pointer
      /studies/8/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      0fdf56bd9be37954e1014d209f828f3c4c5cbd36dd191fb256a62fa077ce3993

    Preserved source evidence · Not medical advice